Loading clinical trials...
Loading clinical trials...
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assess...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
ADARx Pharmaceuticals, Inc.
NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07144137 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07424235 · Age Related Macular Degeneration (AMD), Age Related Macular Degeneration, and more
NCT04770545 · Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Clinical Site
Gilbert, Arizona
ADARx Clinical Site
Phoenix, Arizona
ADARx Clinical Site
Beverly Hills, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions